Axitinib dose titration: what's the limiting factor?
Mené sur 213 patients atteints d'un carcinome métastatique à cellules rénales, cet essai international de phase II évalue, du point de vue du pourcentage de patients avec une réponse objective, l'efficacité et la toxicité d'un titrage individuel de la dose d'axitinib
Pharmacokinetic data suggest that for patients with metastatic renal-cell carcinoma an increased exposure to tyrosine kinase inhibitors could be associated with improved clinical outcome. To date, four approaches to increase drug exposure have been proposed. First, simple dose escalation until unacceptable toxic effects is reached (a strategy which has ultimately failed); second, changing the schedule from the beginning of treatment, or according to toxicity; third, adapting the dose accor ...
The Lancet Oncology , commentaire, 2012